Physicochemical Properties
| Molecular Formula | C23H18N8 |
| Molecular Weight | 406.442622661591 |
| Exact Mass | 406.165 |
| CAS # | 1352609-28-9 |
| PubChem CID | 54767248 |
| Appearance | Off-white to light yellow solid powder |
| LogP | 2.8 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 31 |
| Complexity | 649 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | N1C(CNC2C=CC=C(C#N)C=2)=NC(C2C=CC3=NC=NN3C=2)=C1C1C=CC=C(C)N=1 |
| InChi Key | KEADGKSQIBFYEE-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C23H18N8/c1-15-4-2-7-19(28-15)23-22(17-8-9-21-26-14-27-31(21)13-17)29-20(30-23)12-25-18-6-3-5-16(10-18)11-24/h2-10,13-14,25H,12H2,1H3,(H,29,30) |
| Chemical Name | 3-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-imidazol-2-yl]methylamino]benzonitrile |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | ALK5 4.83 nM (IC50) p38α 1.5 μM (IC50) |
| ln Vitro | Breast cancer cells' EMT, motility, and invasiveness are all inhibited in vitro by EW7195. Effectively inhibiting TGF-β1-induced Smad2 phosphorylation and subsequent Smad2/3 nuclear translocation is EW-7195. TGF-β1-induced mesenchymal morphology is inhibited by EW-7195. TGF-β-induced transcriptional activation is inhibited by EW-7195[1]. TGF-β1-induced Smad2 phosphorylation is effectively inhibited by EW-7195 (0.5–1 µM; 1.5 hours)[1]. |
| ln Vivo | EW7195 (40 mg/kg; ip; three times a week for 3/2.5 weeks) prevents the growth of lung metastases in both MMTV/cNeu transgenic mice and 4T1 orthotopic xenograft mice[1]. |
| Animal Protocol |
Animal/Disease Models: MMTV/c-Neu mice[1] Doses: 40 mg/kg Route of Administration: Ip; three times a week for 3 weeks Experimental Results: Inhibited the metastasis of breast cancer cells to the lung. Animal/Disease Models: Balb/c xenograft model (10-weeks-old female balb/c (Bagg ALBino) mouse bearing 4T1 cells)[1] Doses: 40 mg/kg Route of Administration: Ip; three times a week for 2.5 weeks Experimental Results: Suppressed a lung metastasis in the Balb/c Xenograft model. |
| References |
[1]. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung. Eur J Cancer. 2011;47(17):2642-2653. |
Solubility Data
| Solubility (In Vitro) | DMSO: 50 mg/mL (123.02 mM) |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4604 mL | 12.3019 mL | 24.6039 mL | |
| 5 mM | 0.4921 mL | 2.4604 mL | 4.9208 mL | |
| 10 mM | 0.2460 mL | 1.2302 mL | 2.4604 mL |